<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603251</url>
  </required_header>
  <id_info>
    <org_study_id>ACTIVE</org_study_id>
    <nct_id>NCT01603251</nct_id>
  </id_info>
  <brief_title>Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission</brief_title>
  <acronym>ACTIVE</acronym>
  <official_title>A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and impact of ivermectin, administered
      as single or repeated dose, in combination with artemether-lumefantrine in reducing the
      proportion of mosquitoes that survive and become infected after feeding on a blood meal from
      a malaria-infected individual.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 days</time_frame>
    <description>The number of adverse events; number of participants with abnormal haemoglobin, biochemistry or full blood count values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mosquitocidal activity</measure>
    <time_frame>feeding experiments performed up to 8 days after enrolment; survival of mosquitoes determined up to day 10 after feeding</time_frame>
    <description>Daily mortality rates of (malaria-infected) Anopheles gambiae s.s. and An. funestus mosquitoes after taking a blood meal 1, 3 or 7 days after initiation of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine + single dose Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine + repeated dose Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <description>Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL</description>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination + single dose Ivermectin</intervention_name>
    <description>Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.</description>
    <arm_group_label>Artemether-Lumefantrine + single dose Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination + repeated dose Ivermectin</intervention_name>
    <description>Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.</description>
    <arm_group_label>Artemether-Lumefantrine + repeated dose Ivermectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  asymptomatically infected individuals with any P. falciparum parasite density

        Exclusion Criteria:

          -  age &lt; 15 years or &gt; 25 years

          -  malaria parasite density ≥ 10,000 parasites/µL

          -  clinical symptoms indicating severe malaria

          -  axillary temperature ≥ 37.5°C

          -  Body Mass Index (BMI) below 18 or above 32 kg/m2

          -  haemoglobin concentration below 11 g/dL

          -  taken ivermectin in the last three months

          -  Loa loa as assessed by questionnaire, clinical examination and parasitological
             assessments

          -  for women: pregnancy or lactation

          -  known hypersensitivity to AL or IVM

          -  history and/or symptoms indicating chronic illness

          -  current use of tuberculosis or anti-retroviral medication

          -  unable to give written informed consent

          -  unwillingness to participate in two membrane feeding assays

          -  travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo,
             Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan. If a potential participant has
             ever visited one or more of these countries, he or she will not be eligible for
             enrolment.

          -  history of cardiovascular disease.

          -  taking drugs that are known to influence cardiac function and to prolong QTc interval,
             such as class IA and III: neuroleptics, antidepressant agents, certain antibiotics
             including some agents of the following classes - macrolides, fluoroquinolones,
             imidazole, and triazole antifungal agents, certain non-sedating antihistaminics
             (terfenadine, astemizole) and cisapride.

          -  known disturbances of electrolyte balance, e.g. hypokalaemia or hypomagnesaemia.

          -  taking drugs which may be metabolized by cytochrome enzyme CYP2D6 (e.g., flecainide,
             metoprolol, imipramine, amitriptyline, clomipramine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teun Bousema</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le Paludisme</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transmission</keyword>
  <keyword>anopheles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

